IGI Logo

Below is Mankind Pharma listing by Mr. Hemang Jani, Head Equity Strategy, Motilal Oswal Financial Services

“Mankind Pharma got listed at 20% premium to the IPO price, thus receiving a strong response. The primary market saw an IPO hitting after a long gap, thus the interest was high. Moreover the healthcare sector was a laggard over last one year but started seeing traction over last two months as the monthly pharma data showed improvement. Thus Mankind Pharma received good response from its anchor clients given its domestic focused business with strong brand recall in both chronic and consumer healthcare segment. Given its healthy financial track record, domestic focus and extensive network, Mankind is likely to continue doing well.”

Above views are of the author and not of the website kindly read disclaimer